Ester Munoz-Aceituno
Overview
Explore the profile of Ester Munoz-Aceituno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reolid A, Sahuquillo-Torralba A, Sanz-Garcia A, Botella-Estrada R, Munoz-Aceituno E, Llamas-Velasco M, et al.
J Pers Med
. 2022 Sep;
12(9).
PMID: 36143237
Background: Psoriasis can present different phenotypes and could affect diverse body areas. In contrast to the high effectiveness of biological drugs in the treatment of trunk and extremities plaque psoriasis,...
2.
Reolid A, Martinez-Palazuelo M, Rodriguez-Jimenez P, Munoz-Aceituno E, Llamas-Velasco M, Fraga J, et al.
J Cutan Pathol
. 2022 Mar;
49(8):683-691.
PMID: 35357702
Background: Attempts have been made to establish discriminative criteria between classic calciphylaxis (CPX) and those cases in which cutaneous vascular calcification (CVC) represents an incidental finding (epiphenomenon). Methods: Retrospective, observational...
3.
Llamas-Velasco M, Munoz-Aceituno E, Sanchez-Perez J, Camarero-Mulas C, Fraga J, Aragues M
J Cutan Pathol
. 2021 Nov;
49(4):373-376.
PMID: 34743349
Sclerodermatous graft-versus-host disease (GvHD) is one of the many clinicopathological variants of chronic GvHD. One of the rarest forms of this variant is GvHD-associated angiomatosis (GvHD-AA). We describe the case...
4.
Sanz-Garcia A, Reolid A, Fisas L, Munoz-Aceituno E, Llamas-Velasco M, Sahuquillo-Torralba A, et al.
Acta Derm Venereol
. 2021 Apr;
101(5):adv00448.
PMID: 33846759
Biological drugs targeting tumour necrosis factor are effective for psoriasis. However, 30-50% of patients do not respond to these drugs and may even develop paradoxical psoriasiform reactions. This study search-ed...
5.
Herrero-Moyano M, Munoz-Aceituno E, Fernandez-Figueras M, Fraga J, Llamas-Velasco M
J Dtsch Dermatol Ges
. 2021 Feb;
19(2):268-271.
PMID: 33586897
No abstract available.
6.
Munoz-Aceituno E, Martos-Cabrera L, Ovejero-Benito M, Reolid A, Abad-Santos F, Dauden E
Medicina (Kaunas)
. 2021 Jan;
56(12).
PMID: 33419370
Psoriasis is a chronic immune-mediated skin disease caused by several complex factors, both environmental and genetic, many of which are still not fully understood. Nowadays, several groups of biological drugs...
7.
Herrero-Moyano M, Munoz-Aceituno E, Fernandez-Figueras M, Fraga J, Llamas-Velasco M
J Dtsch Dermatol Ges
. 2020 Oct;
19(2):268-271.
PMID: 33125797
No abstract available.
8.
Ovejero-Benito M, Munoz-Aceituno E, Sabador D, Almoguera B, Prieto-Perez R, Hakonarson H, et al.
Exp Dermatol
. 2020 Oct;
29(12):1225-1232.
PMID: 33058233
While anti-TNF therapies are effective against psoriasis, 30%-50% of patients do not show an adequate response to these drugs. Different candidate-gene pharmacogenetics studies have identified single nucleotide polymorphisms that may...
9.
Rodriguez-Jimenez P, Munoz-Aceituno E, Vargas E
Cutis
. 2020 Sep;
106(2):E21-E22.
PMID: 32941568
No abstract available.
10.
Chicharro P, Rodriguez-Jimenez P, Munoz-Aceituno E, De Argila D, Munoz-Hernandez P, Llamas-Velasco M
Australas J Dermatol
. 2020 Aug;
62(1):88-89.
PMID: 32815151
No abstract available.